Sector News

Stryker announces commercial structure realignment

August 19, 2019
Life sciences

Stryker has announced an adjustment to its commercial organizational structure. Spencer S. Stiles will serve as Group President of Orthopaedics and Spine and will oversee Stryker’s Joint Replacement, Trauma & Extremities and Spine divisions. J. Andrew Pierce, Group President of MedSurg and Neurotechnology will oversee Stryker’s Instruments, Medical, Endoscopy, Sustainability and Neurotechnology businesses.

Mr. Stiles and Mr. Pierce have both served at Stryker for over 20 years and will continue to report to Timothy J. Scannell, President and Chief Operating Officer in their newly expanded roles. Since August of 2018, Mr. Scannell has been responsible for all of the company’s commercial businesses and regions. This change will further accelerate the globalization and collaboration opportunities being unlocked in this structure and leverage the diverse experience of these leaders.

Stuart F. Simpson, President of Joint Replacement has left the company to pursue other career interests.

Source: Stryker

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach